San Diego, Dec. 13, 2011 (Shareholders Foundation) -- The announcement that Synovis Life Technologies. agreed to be acquired by Baxter International for $28 per share prompted an investigation for investors in shares of Synovis Life Technologies, Inc. (NASDAQ:SYNO) concerning whether the offer to acquire Synovis Life Technologies and the buyout process are unfair to investors in NASDAQ:SYNO and whether certain of its officers and directors at Synovis Life Technologies or others breached their fiduciary duties.

The investigations by law firms concern whether Synovis Life Technologies, certain of its officers and directors, and/or others breached their fiduciary duties owed Synovis Life Technologies, Inc. (NASDAQ:SYNO) investors in connection with the proposed acquisition.

On December 13, 2011, Synovis Life Technologies, Inc. (NASDAQ:SYNO) and Baxter International Inc. (NYSE:BAX) announced an agreement for Baxter Intl. to acquire Synovis Life Technologies. Under the proposed transaction shareholders of Synovis Life Technologies, Inc. (NASDAQ:SYNO) will received $28 per NASDAQ: SYNO shares, which equates to $325 million of equity value or approximately $260 million after adjusting for the net cash.

Following the takeover proposal shares of Synovis Life Technologies, Inc. (Public, NASDAQ:SYNO) jumped from $18.44 on December 12 to $27.78 per share on December 13, 2011.

However, Synovis Life Technologies financial performance increased lately. IN fact, Synovis Life Technologies annual Revenue rose from $37.69million for 2007 to $68.56million in 2010 and its Net Income increased over the same time periods from $3.81million to $4.88million. Its second quarter Revenue rose from $17.64million last year to $21.02million this year and its second quarter Net Income increased from $1.51million a year ago to $1.99million this year.

Therefore the investigation for investors concerns whether the Synovis Life Technologies Board of Directors undertook an adequate sales process and in particular breached their fiduciary duties to Synovis Life Technologies (SYNO) shareholders by failing to adequately shop the Company before entering into this transaction.

A potential securities class action lawsuit would seek to maximize the amount of money and information NASDAQ:SYNO shareholders would receive in a buyout, so the law firm.